The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Open accessAbstract
In multicellular organisms, communication between individual cells is essential for the regulation and coordination of complex cellular processes such as growth, differentiation, migration and apoptosis. The plethora of signal transduction networks mediating these biological processes is regulated in part by polypeptide growth factors that can generate signals by activating cell surface receptors either in paracrine or autocrine manner. The primary mediators of such physiological cell responses are receptor tyrosine kinases (RTKs) that couple ligand binding to downstream signalling cascades and gene transcription. Investigations over the past 18 years have revealed that RTKs are not only key regulators of normal cellular processes but are also critically involved in the development and progression of human cancers. Therefore, signalling pathways controlled by tyrosine kinases offer unique opportunities for pharmaco logical intervention. The aim of this review is to give a broad overview of RTK signalling involved in tumorigenesis and the possibility of target-selective intervention for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationBiochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Self-citationInsulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Protein modules and signalling networks
Pawson, T. (1995) · Nature · doi:10.1038/373573a0 · Cited by 2,420
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Molecular and cellular endocrinology
(1995) · Journal of Endocrinology · doi:10.1677/joe.0.147so19 · Cited by 1,991
GROWTH FACTOR RECEPTOR TYROSINE KINASES
Yarden, Y., & Ullrich, A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002303 · Cited by 1,838
Self-citationCoussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citationAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Dimerization of cell surface receptors in signal transduction
Heldin, C.-H. (1995) · Cell · doi:10.1016/0092-8674(95)90404-2 · Cited by 1,634
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways
van der Geer, P., Hunter, T., & Lindberg, R. A. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.001343 · Cited by 1,326
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Self-citationThe neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
The Fgf Family of Growth Factors and Oncogenes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60305-x · Cited by 1,145
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Self-citationBargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Specificity within the EGF family/ErbB receptor family signaling network
Riese, D. J., & Stern, D. F. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v · Cited by 809
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Self-citationSignal transduction via platelet-derived growth factor receptors
Heldin, C.-H., Östman, A., & Rönnstrand, L. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00015-8 · Cited by 742
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Alroy, I., & Yarden, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00412-2 · Cited by 714
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G., Zarnegar, R., Michalopoulos, G. K., & Comoglio, P. M. (1991) · PubMed · Cited by 698
Sonnenberg, E., Meyer, D., Weidner, K. M., & Birchmeier, C. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.1.223 · Cited by 698
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Self-citationPrewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 659
Spivak-Kroizman, T., Lemmon, M. A., Dikic, I., Ladbury, J. E., Pinchasi, D., Huang, J., Jaye, M., Crumley, G., Schlessinger, J., & Lax, I. (1994) · Cell · doi:10.1016/0092-8674(94)90032-9 · Cited by 658
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · cited 1×
“Somatic mutations in the FGFR-3, similar to the activating mutations in skeletal dysplasias, have been identified in bladder cancer and in multiple myeloma (Chesi et al. 1997, Capellen et al. 1999).”
BackgroundMolecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase
Birchmeier, C., & Gherardi, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01359-2 · Cited by 597
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Bruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 498
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Self-citationTyrosine kinase receptor indistinguishable from the c-met protein
Giordano, S., Ponzetto, C., Renzo, M. F. D., Cooper, C. S., & Comoglio, P. M. (1989) · Nature · doi:10.1038/339155a0 · Cited by 490
Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis
Burden, S., & Yarden, Y. (1997) · Neuron · doi:10.1016/s0896-6273(00)80324-4 · Cited by 476
Renzo, M. F. D., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., & Giordano, S. (1995) · PubMed · Cited by 471
Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., & Ullrich, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204192 · Cited by 462
Self-citationOverexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., & Greene, M. I. (1989) · Nature · doi:10.1038/339230a0 · Cited by 423
Kaleko, M., Rutter, W. J., & Miller, A. D. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.2.464 · Cited by 409
Grandis, J. R., Melhem, M. F., Barnes, E. L., & Tweardy, D. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960915)78:6<1284::aid-cncr17>3.0.co;2-x · Cited by 369
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
Levitzki, A. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.14.1426765 · Cited by 317
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999) · PubMed · Cited by 311
Fontanini, G., Laurentiis, M. D., Vignati, S., Chinè, S., Lucchi, M., Silvestri, V., Mussi, A., Placido, S. D., Tortora, G., Bianco, A. R., et al. (1998) · PubMed · Cited by 306
Signaling by dual specificity kinases
Dhanasekaran, N., & Reddy, E. P. (1998) · Oncogene · doi:10.1038/sj.onc.1202251 · Cited by 301
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
Self-citationProtein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 288
Self-citationWang, Y., & Becker, D. (1997) · Nature Medicine · doi:10.1038/nm0897-887 · Cited by 284
Giri, D., Ropiquet, F., & Ittmann, M. (1999) · PubMed · Cited by 280
Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Krystal, G. W., Hines, S. J., & Organ, C. P. (1996) · PubMed · Cited by 266
Huang, S.-M., & Harari, P. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006384521198 · Cited by 253
Park, W. S., Dong, S. M., Kim, S. Y., Na, E. Y., Shin, M. S., Pi, J. H., Kim, B. J., Bae, J. H., Hong, Y. K., Lee, K. S., et al. (1999) · PubMed · Cited by 251
Growth Factors in Glioma Angiogenesis: FGFs, PDGF, EGF, and TGFs
Dunn, I. F., Heese, O., & Black, P. M. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006436624862 · Cited by 246
Kan, M., Zhang, G., Zarnegar, R., Michalopoulos, G., Myoken, Y., McKeehan, W. L., & Stevens, J. L. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)90524-b · Cited by 246
Mendel, D. B., Laird, A., Smolich, B. D., Blake, R., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., et al. (2000) · PubMed · Cited by 230
Molecular Mechanisms of Developmental and Tumor Angiogenesis
Plate, K. H., Breier, G., & Risau, W. (1994) · Brain Pathology · doi:10.1111/j.1750-3639.1994.tb00835.x · Cited by 227
Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., & Dinney, C. P. (2000) · PubMed · Cited by 225
The mutationally activated Met receptor mediates motility and metastasis
Jeffers, M., Fiscella, M., Webb, C. P., Anver, M., Koochekpour, S., & Vande Woude, G. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14417 · Cited by 224
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220
Immunotoxins in cancer therapy
Kreitman, R. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00005-9 · Cited by 215
Function of the IGF-I Receptor in Breast Cancer
Surmacz, E. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009523501499 · Cited by 214
Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents
Levitzki, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00066-7 · Cited by 214
Eng, C., & Mulligan, L. M. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m · Cited by 212
Natali, P. G., Nicotra, M. R., Winkler, A. B., Cavaliere, R., Bigotti, A., & Ullrich, A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520207 · Cited by 211
Self-citationHER2/Neu: mechanisms of dimerization/oligomerization
Brennan, P. J., Kumogai, T., Berezov, A., Murali, R., & Greene, M. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203967 · Cited by 185
Noonberg, S. B., & Benz, C. C. (2000) · Drugs · doi:10.2165/00003495-200059040-00003 · Cited by 173
Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J. G., & Seely, B. L. (1998) · PubMed · Cited by 173
RET mutations in human disease
Pasini, B., Ceccherini, I., & Romeo, G. (1996) · Trends in Genetics · doi:10.1016/0168-9525(96)10012-3 · Cited by 172
Greenfield, C., Hiles, I., Waterfield, M. D., Federwisch, M., Wollmer, A., Blundell, T. L., & McDonald, N. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08596.x · Cited by 169
Recombinant antibody constructs in cancer therapy
Hudson, P. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00013-8 · Cited by 169
RTK mutations and human syndromes: when good receptors turn bad
Robertson, S. C., Tynan, J., & Donoghue, D. J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02077-1 · Cited by 168
Overholser, J. P., Prewett, M. C., Hooper, A. T., Waksal, H. W., & Hicklin, D. J. (2000) · Cancer · doi:10.1002/1097-0142(20000701)89:1<74::aid-cncr11>3.0.co;2-k · Cited by 165
Siegfried, J. M., Weissfeld, L. A., Singh-Kaw, P., Weyant, R. J., Testa, J. R., & Landreneau, R. J. (1997) · PubMed · Cited by 164
Bispecific antibodies in cancer therapy
Segal, D. M., Weiner, G. J., & Weiner, L. M. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00015-1 · Cited by 161
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
Neve, R. M., Sutterlüty, H., Pullen, N., Lane, H. A., Daly, J. M., Krek, W., & Hynes, N. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203470 · Cited by 158
Substrate Competitive Inhibitors of IGF-1 Receptor Kinase
Blum, G., Gazit, A., & Levitzki, A. (2000) · Biochemistry · doi:10.1021/bi001516y · Cited by 151
Constitutive expression of steel factor gene by human stromal cells
Heinrich, M. C., Dooley, D., Freed, A., Band, L., Hoatlin, M. E., Keeble, W., Peters, S., Silvey, K. V., Ey, F., & Kabat, D. (1993) · Blood · doi:10.1182/blood.v82.3.771.771 · Cited by 146
The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia.
Wang, C., Curtis, J. E., Geissler, E. N., Ea, M., & Minden, M. D. (1989) · PubMed · Cited by 145
Prewett, M. C., Rothman, M., Waksal, H. W., Feldman, M. A., Bander, N. H., & Hicklin, D. J. (1998) · PubMed · Cited by 141
Takano, S., Gately, S. T., Neville, M. E., Herblin, W. F., Gross, J. L., Engelhard, H. H., Perricone, M. A., Eidsvoog, K., & Brem, S. S. (1994) · PubMed · Cited by 131
Antiangiogenic Strategies and Agents in Clinical Trials
Rosen, L. S. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-20 · Cited by 122
Therapeutic application of anti-growth factor receptor antibodies
Fan, Z., & Mendelsohn, J. M. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199801000-00011 · Cited by 119
Signaling antibodies in cancer therapy
Cragg, M. S., French, R. R., & Glennie, M. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00010-2 · Cited by 119
Lonardo, F., Marco, E. D., King, C. R., Pierce, J. H., Segatto, O., Aaronson, S. A., & Fiore, P. P. D. (1990) · PubMed · Cited by 115
Development of inhibitors for protein tyrosine kinases
Al‐Obeidi, F., & Lam, K. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203926 · Cited by 111
Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors
Rasmussen, A. A., & Cullen, K. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005903000777 · Cited by 104
Kornmann, M., Ishiwata, T., Beger, H. G., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201307 · Cited by 100
Grandis, J. R., Chakraborty, A., Zeng, Q., Melhem, M. F., & Tweardy, D. J. (1998) · Journal of Cellular Biochemistry · Cited by 97
Brodt, P., Samani, A. A., & Navab, R. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00422-6 · Cited by 94
Schmidt, L. S., Duh, F. M., Chen, F., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00035 · Cited by 87
Seth, D., Shaw, K., Jazayeri, J. A., & Leedman, P. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690407 · Cited by 86
Transformation of thyroid epithelium is associated with loss of c-kit receptor.
Natali, P. G., Berlingieri, M. T., Nicotra, M. R., Fusco, A., Santoro, E., Bigotti, A., & Vecchio, G. (1995) · PubMed · Cited by 81
Ret in human development and oncogenesis
Edery, P., Münnich, A., Lyonnet, S., et al. (1997) · BioEssays · doi:10.1002/bies.950190506 · Cited by 79
Li, Y., Basilico, C., & Mansukhani, A. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7660 · Cited by 71
Structure, function and transforming potential of the epidermal growth factor receptor
Velu, T. J. (1990) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(90)90211-p · Cited by 66
Hsieh, E., Shepherd, F. A., & Tsao, M. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00116-1 · Cited by 66
Schmidt, L. S., Duh, F. M., Chen, F., et al. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)63909-0 · Cited by 65
Maurer-Gebhard, M., Schmidt, M., Azémar, M., et al. (1998) · PubMed · Cited by 51
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris, H. A. (2000) · PubMed · Cited by 50
Shingū, K., FUJIMORI, M., Ito, K., et al. (1998) · Endocrine Journal · doi:10.1507/endocrj.45.35 · Cited by 41
Pawlak, W., Żołnierek, J., Sarosiek, T., & Szczylik, C. A. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0173 · Cited by 35
Preclinical and Clinical Pharmacology of Antisense Oligonucleotides
Marcusson, E. G., Yacyshyn, B., Shanahan, W. R., & Dean, N. M. (1999) · Molecular Biotechnology · doi:10.1385/mb:12:1:1 · Cited by 32
Roh, H., Hirose, C. B., Boswell, C., Pippin, J. A., & Drebin, J. A. (1999) · Surgery · doi:10.1016/s0039-6060(99)70186-8 · Cited by 26
Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Breast Cancer
Perks, C. M., & Holly, J. M. P. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009519400591 · Cited by 25
HER2/neu: A Target for Breast Cancer Therapy
Zwick, E., Wallasch, C., & Ullrich, A. (2000) · Breast Disease · doi:10.3233/bd-1999-11102 · Cited by 11
Self-citation
Cited by
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Thiazole-containing compounds as therapeutic targets for cancer therapy
Sharma, P. C., Bansal, K. K., Sharma, A., Sharma, D., & Deep, A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112016 · Cited by 382
Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation
Changeux, J.-P., & Christopoulos, A. (2016) · Cell · doi:10.1016/j.cell.2016.08.015 · Cited by 336
The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors
Ritter, C. A., & Arteaga, C. L. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50027 · Cited by 311
Metadata
- Authors
- Zwick, E., Bange, J., & Ullrich, A.
- Venue
- Endocrine-related cancer
- Publisher
- Bioscientifica
- Published
- 2001-09
- Volume
- 8
- Issue
- 3
- Pages
- 161-173
- ISSN
- 1351-0088 (ISSN-L)
- OpenAlex
- W2142776762
- Cited by
- 384
- References
- 124
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.